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Although there is considerable genetic and pathologic 
evidence for an association between neuregulin 1 (NRG1) 
dysregulation and schizophrenia, the underlying molecu-
lar and cellular mechanisms remain unclear. Mutant 
mice containing disruption of the transmembrane (TM) 
domain of the NRG1 gene constitute a heuristic model 
for dysregulation of NRG1-ErbB4 signaling in schizo-
phrenia. The present study focused on hitherto unchar-
acterized information processing phenotypes in this 
mutant line. Using a mass spectrometry-based metab-
olomics approach, we also quantified levels of unique 
metabolites in brain. Across 2 different sites and pro-
tocols, Nrg1 mutants demonstrated deficits in prepulse 
inhibition, a measure of sensorimotor gating, that is, 
disrupted in schizophrenia; these deficits were partially 
reversed by acute treatment with second, but not first-, 
generation antipsychotic drugs. However, Nrg1 mutants 
did not show a specific deficit in latent inhibition, a 
measure of selective attention that is also disrupted in 
schizophrenia. In contrast, in a “what–where–when” 
object recognition memory task, Nrg1 mutants dis-
played sex-specific (males only) disruption of “what–
when” performance, indicative of impaired temporal 
aspects of episodic memory. Differential metabolomic 
profiling revealed that these behavioral phenotypes were 
accompanied, most prominently, by alterations in lipid 
metabolism pathways. This study is the first to associate 
these novel physiological mechanisms, previously inde-
pendently identified as being abnormal in schizophrenia, 
with disruption of NRG1 function. These data suggest 
novel mechanisms by which compromised neuregulin 
function from birth might lead to schizophrenia-relevant 
behavioral changes in adulthood.
Key words:  mutant phenotype/cognition/metabolome/
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Introduction
Neuregulin-1 (NRG1) is a gene that has been associated 
with increased risk for schizophrenia across diverse pop-
ulations.1–3 Studies on postmortem brain and serum from 
schizophrenia cases have reported up-regulation of spe-
cific NRG1/ErbB4 splice variants and increased NRG1 
signaling,4–9 and decreased isoform-specific expression 
of NRG1 transcripts.9,10 However, despite such combined 
genetic and pathologic evidence for NRG1 dysregulation 
in schizophrenia, the mechanisms underlying this asso-
ciation remain unclear.11
Multiple NRG1 isoforms have been described, the 
diversity of which is due to alternative splicing and the 
existence of multiple 5′ flanking regulatory elements. 
NRG1 I–III, share the EGF–like signaling domain; 
interaction of these EGF-like domains with membrane-
associated tyrosine kinases (ErbB receptors) activates 
intracellular signaling pathways.12–14 NRG1/ErbB4 signal-
ing has been associated with various neurodevelopmental 
and plasticity-related processes, including synapse forma-
tion, neuronal migration, and neurotransmitter receptor 
development and function.13 Altered NRG1 expression 
has been identified in several schizophrenia-relevant 
rodent models,15–17 and several Nrg1 knockout/transgenic 
mouse lines have been developed to study the impact of 
altered NRG1 signaling on endophenotypes relevant 
to schizophrenia.18,19 The most well-characterized Nrg1 
mutant model involves heterozygous deletion of the 
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transmembrane domain of the Nrg1 gene; this model 
demonstrates behavioral and cellular phenotypes related 
to schizophrenia, as well as disturbance in schizophrenia-
relevant (dopaminergic, GABAergic, glutamatergic) neu-
rotransmission.19,20 Recent work has suggested that the 
TM-domain Nrg1 mutant is not a straightforward model 
of NRG1 haploinsufficiency, but may be better character-
ized as a model of imbalanced NRG1-ErbB4 signaling.21
Cognitive dysfunction is highly prevalent in schizo-
phrenia, and there is consensus that impairments in 
working memory, executive function, and attention 
are core features.22 These cognitive impairments are of 
particular significance for the disease, as they are more 
closely associated with poor outcome in patients.23,24 
Prepulse inhibition (PPI) and latent inhibition (LI) mea-
sure sensory gating and selective attention processes, 
respectively. Patients with schizophrenia show disrupted 
PPI and LI task performance, and these deficits are con-
sidered to reflect aberrant salience processing, that is, at 
the interface of psychotic symptoms and cognitive dys-
function.25–30 Patients with schizophrenia also show pro-
found impairment in episodic memory,31,32 which refers 
to a cross-modal form of memory that encompasses not 
only the memory for an event (“what”), but also its spa-
tial (“where”) and temporal (“when”) characteristics.33 
TM-domain Nrg1 mutants demonstrate intact spatial 
learning and working memory,34 but subtle deficits in 
contextual fear conditioning, cued aversion, and novel 
object recognition.35,36 While disruption to PPI has been 
reported, though in a manner highly sensitive to protocol 
and stress-related environmental factors,18,19,30,37 episodic 
memory and detailed examination of preattentional and 
selective attention processing has not been conducted in 
the TM-domain Nrg1 mutant line.
The relative failure to develop novel antipsychotic 
drugs in recent decades reflects, in part, incomplete 
understanding of disease mechanisms, and the absence 
of treatment biomarkers.38 Metabolomic analysis, which 
provides a snapshot of the current status of biochemical 
pathways, can provide additional information on path-
ways affected in disease pathobiology.39,40 For example, 
metabolomic characterization of brain tissue from mice 
containing a knockout of the Npas3 gene, which has been 
independently associated with increased risk for schizo-
phrenia,41,42 has revealed differential expression of gly-
colysis pathway metabolites.39
In the following study, we examined whether 
TM-domain Nrg1 mutant mice show abnormalities in per-
formance measures of LI, PPI, and an episodic memory 
(“what–where–when”) paradigm. Because of controversies 
regarding PPI disruption in this mutant line,18,19,30 we also 
examined whether acute treatment with selected first- or 
second-generation antipsychotic drugs was able to ame-
liorate PPI deficits. We then investigated the underlying 
neurobiology of Nrg1 mutants via high-resolution mass-
spectrometry-based metabolomic analysis of brain tissue.
Methods
Ethics Statement
All mouse studies conducted in University of 
Nottingham, UK, were performed in accordance with 
local and national rules on animal experimentation, and 
with appropriate personal and project license authority 
under the Animals (Scientific Procedures) Act, UK 1986 
(PPL no: 40/2883). All mouse studies conducted at RCSI, 
Dublin, were approved by the Research Ethics Committee 
of RCSI, and were conducted under license from the 
Department of Health and Children in accordance with 
Irish legislation and the European Communities Council 
Directive 86/609/EEC for the care and use of experimen-
tal animals.
Animals
Mice with heterozygous transmembrane-domain dele-
tion of Nrg1 were originally generated at the Victor 
Chang Cardiac Research Institute, University of New 
South Wales, Australia, as described previously.34,43 The 
TM-domain Nrg1 mutant line was maintained on a 
C57BL/6 background, with experimental animals gen-
erated from heterozygous breeding pairs and genotyped 
using PCR.
In this report, 2 cohorts of TM-domain Nrg1 mutants 
were used, each tested at different phenotyping facili-
ties. Both groups of experimental animals were bred and 
weaned at the Biomedical Research Facility at RCSI, 
Dublin: mice used in the LI, PPI (without drug treat-
ment), and episodic memory studies were shipped to the 
housing facility at the University of Nottingham at 7–10 
weeks of age, with testing commencing 3 weeks after 
arrival; mice used in the PPI study with drug treatment 
were tested at RCSI, Dublin. In both facilities, mice were 
housed in groups of 3–5 per cage and maintained at 21°C 
on a 12-hour light/dark cycle (lights on 08:00 hours), 
with food and water available ad libitum. At Nottingham 
Mice were housed in individually ventilated cages (IVC) 
(Tecniplast) in cages with a floor area 501 sq cm, with the 
following cage dimensions: 391  mm L × 199  mm W × 
160 mm H. Cages had a play tunnel and shredded paper 
nesting material. At the Dublin facility, mice were housed 
in IVC cages (Animal Care Systems) in cages with a floor 
area of 535 sq cm, with the following cage dimensions: 
389 mm L × 198 mm W × 241 mm H. Shredded paper 
nesting material was added.
Experimental Design
LI, PPI (Nottingham), and episodic memory testing, in 
that order, were carried out in adult (10–12 weeks) male 
and female WT (n  =  16; 8 male, 8 female) and Nrg1 
mutants (n = 15; 7 male, 8 female). In the study examining 
the effects of antipsychotic treatment on PPI (Dublin), 
adult male mice of each genotypes (8–12 per treatment 
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condition, 16–20 weeks) were treated with either vehicle 
(WT, n = 9; Nrg1, n = 15), haloperidol (0.5 mg/kg; WT, 
n = 7; NRG1, n = 7), clozapine (1 mg/kg; WT, n = 7; Nrg1, 
n = 9), or amisulpride (5 mg/kg; WT, n = 9; Nrg1, n = 7). 
Thirty minutes later, all mice underwent PPI testing. 
Metabolomic analysis was carried out in whole brains of 
male WT (n = 4) and Nrg1 mutants (n = 4). As previous 
studies have indicated significant sex effects on behav-
ioral parameters in these and related mice,34,44 we have 
presented data split by sex for comparative purposes. We 
were unable to include site as an ANOVA variable as one 
cohort received injections (Dublin) while the other did 
not (Nottingham).
Behavioral and psychopharmacological protocols, as 
well as the metabolomics methods are available in the 
online supplementary material.
Data Analysis
Statistical analysis of behavioral and psychopharma-
cological data was performed using SPSS v.20 (SPSS, 
Inc.). For all measures, independent or repeated mea-
sures analysis of variance (ANOVA) was used with main 
factors of genotype (Nrg1 mutant/WT), and sex (male/
female). Further information regarding statistical meth-
ods, including those used for metabolomics analyses, is 
available in the online supplementary material.
Results
Latent Inhibition Performance in TM-Domain Nrg1 
Mutants
Disrupted LI has been demonstrated in various mutant 
mouse models of schizophrenia.45,46 LI was assessed using 
a conditioned lick suppression paradigm, where intact LI 
comprises reduced learning of a conditioned stimulus 
(CS)–unconditioned stimulus (US) association in a group 
pre-exposed to that stimulus without reinforcement (pre-
exposed, PE) compared with a group without such pre-
exposure (non–pre-exposed, NPE).45 A significant effect 
of pre-exposure was observed on suppression ratio (SR) 
values (F1,54 = 11.96, P < .01), in a manner indicative of 
intact LI. However, LI was not modified by genotype 
(F1,54 = 3.04, P > .05), sex (F1,54 = 1.53, P > .05), or any 
interaction between these factors (F1,54 = 0.12, P > .05; 
figure 1A). Further analysis is shown in the supplemen-
tary data section.
An alternative approach to measuring conditioned 
lick suppression in the LI paradigm is to express it as the 
log10 of the T2 values based on time (seconds) taken to 
resume licking after CS onset in the NPE and PE condi-
tions.45 Pre-exposure significantly reduced the time taken 
to complete licks (log10 times) (F1,54  =  11.64, P < .01), 
demonstrating that LI was also observed employing 
this alternative index. No significant effect of genotype 
(F1,54 = 2.11, P > .05) was observed but the analysis of SR 
Fig. 1. Latent inhibition (LI) and pre-pulse inhibition (PPI) 
in Nrg1 mutants. (A) A significant effect of pre-exposure (ie, 
non–pre-exposed [NPE] vs pre-exposed [PE]) on the suppression 
ratio (SR) was observed (P < .01); **P < .01 vs NPE. No 
genotype × exposure interaction was observed. Split by sex, 
male Nrg1 displayed lower SR values relative to wild-type (WT) 
controls (P < .05); #P < .05 vs male WT. No other effects of sex, 
genotype × sex, or genotype × sex × exposure interaction effects 
were observed. Data are mean SR ± SEM. (B) Based on log10 
transformation of T2 values (time in seconds in NPE and PE 
conditions taken to resume licking after conditioned stimulus 
[CS] onset), a significant effect of exposure on log10 T2 times was 
observed (P < .01); ‡‡P < .01 vs NPE. A significant genotype × sex 
effect was observed, indicative of increased T2 times across both 
exposure conditions in male Nrg1 mutants relative to WT  
(P < .05); #P < .05 vs male WT. Data are mean log10-transformed 
T2 values ± SEM. (C) % PPI is significantly decreased in Nrg1 
mutants vs WT at a pulse intensity of 120 dB and 4 pre-pulse 
intensity levels (3, 7, 15, and 25 dB above background)  
(P < .05); *P < .05 vs WT. These data were collected at University 
of Nottingham (see online supplementary material). No genotype 
× prepulse intensity or genotype × sex interaction effect was 
observed. Data are mean % PPI ± SEM.
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data revealed that male mice, and particularly male Nrg1 
mutants, demonstrated an overall reduction in log10 times 
(sex, F1,54  =  4.14, P  <  .05; genotype × sex, F1,54  =  5.03, 
P  <  .05; figure  1B). However, they demonstrated no LI 
deficit, as evidenced by the absence of any significant gen-
otype by exposure by sex interaction (F1,54 = 0.89, P > .05).
Prepulse Inhibition Performance in TM-Domain Nrg1 
Mutants
These PPI data were collected at the University of 
Nottingham, Nottingham, UK (see Methods and 
online supplementary material for study design and 
methodology).
Startle Response/Habituation. Analysis of the startle 
response elicited by the 120 dB pulse revealed no effect 
of genotype (F1,54  =  2.40, P > .05), sex (F1,54  =  1.29, 
P > .05), or genotype × sex interaction (F1,54  =  0.24, 
P > .05; supplementary table  1A). Repeated measures 
ANOVA revealed habituation of the startle response 
(F1,54 = 14.80, P < .01). No significant effect of genotype 
(F1,54 = 3.06, P > .05), sex (F1,54 = 1.62, P > .05), or geno-
type × sex (F1,54 = 0.05, P > .05) was shown in relation to 
startle habituation (supplementary figure 1).
Prepulse Inhibition. A repeated measures ANOVA 
showed that there was a significant effect of prepulse 
intensity on % PPI (F3,162 = 4.44, P < .01; figure 1C). Nrg1 
mutants demonstrated significant disruption in PPI lev-
els (F1,54 = 5.72, P < .05), but this genotypic effect was 
not modulated by pre-pulse intensity level (F1,54 = 1.65, 
P > .05; figure 1C). No effect of sex (F1,54 = 0.001, P > .05), 
or genotype × sex interaction (F1,54 = 0.25, P > .05) was 
observed.
Effects of Acute First- and Second-Generation 
Antipsychotic Drug Administration on PPI in 
TM-Domain Nrg1 Mutants
These PPI data were collected at the Royal College of 
Surgeons in Ireland (RCSI), Dublin, Ireland (see Methods 
and online supplementary material for study design and 
methodology).
Startle Response/Habituation. No significant effect 
of Nrg1 genotype, treatment or genotype × treatment 
interaction was observed in relation to startle response 
to the 100 dB (genotype, F1,61 = 2.53, P > .05; treatment, 
F3,61 = 1.64, P > .05; genotype × treatment, F3,61 = 0.37, 
P > .05), 110 dB (genotype, F1,61 = 0.10, P > .05; treatment, 
F3,61 = 2.13, P > .05; genotype × treatment, F3,61 = 0.61, 
P > .05), or 120 dB pulse-alone intensities (genotype, 
F1,61 = 2.53, P > .05; treatment, F3,61 = 1.64, P > .05; gen-
otype × treatment, F3,61 = 0.37, P > .05; supplementary 
table 1B). Measurement of startle responsivity before and 
after trial blocks demonstrated habituation at a pulse-
alone intensity of 120 dB (trial block: F1,61 = 5.29, P < .05), 
but no habituation of startle response was observed at 
the 100 dB pulse-alone intensity (trial block: F1,61 = 0.99, 
P > .05) or the 110 dB pulse-alone intensity (trial block: 
F1,61 = 2.41, P > .05). At the 100 dB pulse-alone intensity, 
antipsychotic treatment impacted upon startle habitu-
ation (treatment × trial block interaction: F3,61  =  4.64, 
P < .01); individual vehicle vs treatment ANOVA com-
parisons revealed that habituation of startle response was 
observed in amisulpride-treated mice only (F1,36 = 11.19, 
P < .01). Similarly, at the 120 dB pulse-alone inten-
sity, antipsychotic treatment significantly altered startle 
habituation (treatment × trial interaction: F3,61  =  3.82, 
P < .05). Again, individual vehicle vs treatment ANOVA 
comparisons demonstrated that startle habituation was 
shown in amisulpride-treated mice only (F1,36  =  11.19, 
P < .01; supplementary figure 2).
Prepulse Inhibition. At the 100 dB pulse-alone intensity, 
antipsychotic treatment enhanced PPI in a genotype-inde-
pendent manner (treatment, F2,61 = 5.03, P < .01; vehicle 
vs amisulpride, F1,38 = 9.61, P < .01; vehicle vs haloperi-
dol, F1,36 = 5.83, P < .05; vehicle vs clozapine, F1,39 = 14.60, 
P < .01). However, at the same pulse intensity, clozapine 
exerted greater PPI enhancing effects in Nrg1 mutants rel-
ative to other treatment conditions (genotype × treatment 
interaction, F3,61 = 3.51, P < .05; figure 2A). At the 110 dB 
pulse-alone intensity, no effect of genotype, sex, genotype 
× sex, or treatment × sex interaction was demonstrated (all 
P > .05) However, At 120 dB, Nrg1 mutants showed dis-
ruption of PPI at the 4 dB pre-pulse condition (genotype 
× pre-pulse intensity interaction, F2,122 = 3.41, P < .05). 
This deficit was selectively reversed by antipsychotic treat-
ment (genotype × pre-pulse intensity × treatment inter-
action, F6,122 = 3.18, P < .05); ANOVA comparisons for 
each individual treatment vs vehicle at the 4 dB prepulse 
condition revealed that reversal effects were restricted 
to mice treated with clozapine (genotype × prepulse 
intensity × treatment interaction, F2,74 = 4.98, P < 0.05; 
figure 2B). At the 16 dB prepulse condition, antipsychotic 
treatment selectively increased PPI at the 16 dB pre-pulse 
condition in Nrg1 mutants (genotype × prepulse intensity 
× treatment interaction, F6,122  =  3.18, P < .05); individ-
ual ANOVA comparisons revealed that this treatment vs 
vehicle difference was observed only in mice administered 
amisulpride (genotype × prepulse intensity × treatment 
interaction, F2,72 = 3.82, P < .05; figure 2B). At 120 dB, 
haloperidol administration did not significantly alter PPI 
in either Nrg1 or WT mice (treatment, F1,34 = 0.77, P > .05; 
genotype × treatment interaction, F1,34 = 1.29, P > .05).
Episodic Memory in TM-Domain Nrg1 Mutants
Recency Discrimination [“What–When”] Analysis Using 
Mean Discrimination Ratios. One-way between-groups 
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ANOVA on preference for old vs new objects as a discrim-
ination ratio demonstrated a genotype × sex interaction 
(F1,27 = 4.80, P < .05). On splitting the data by sex, while 
female Nrg1 mutants did not differ from WT in prefer-
ence for old vs new objects (F1,14 = 1.42, P > .05), male 
Nrg1 mutants showed reduced preference for old vs new 
objects relative to WT (F1,13 = 5.745, P < .05; figure 3A).
Recency Discrimination [“What–When”] Analysis Using 
Mean Exploration Times. Repeated measures ANOVA 
showed a main effect of familiarity in terms of mean 
time spent exploring old (previously introduced) objects 
vs new (recently introduced) objects (F1,27  =  28.91, 
P < .001). Mean time spent exploring old objects vs new 
objects was unaffected by genotype (F1,27 = 0.65, P > .05), 
sex (F1,27 = 2.17, P > .05), and the genotype × sex inter-
action did not reach statistical significance (F1,27 = 2.31, 
P =  .10). To further explore putative sex-specific effects 
of TM-domain Nrg1 mutation,34 repeated measures 
ANOVAs split by sex were conducted. In females, while 
familiarity influenced mean time spent exploring old vs 
new objects (F1,14  =  16.14, P < .01), no effect of geno-
type was evident (F1,14 = 0.39, P > .05). In males, while 
familiarity influenced mean time spent exploring old vs 
new objects (F1,14 = 13.56, P < .01), Nrg1 mutants dem-
onstrated reduced time exploring new objects, reflecting 
short-term memory impairment in this “what–when” 
domain (F1,14 = 5.73, P < .05; figure 3B).
Recency Discrimination [“What–Where”] Analysis 
Using Discrimination Ratios. One-way between-groups 
ANOVA on preference for stationary vs displaced objects 
as a discrimination ratio showed no effect of genotype 
(F1,27 = 0.14, P > .05), sex (F1,27 = 0.09, P > .05), or geno-
type × sex interaction (F1,27 = 0.22, P > .05; figure 3C). 
One sample t-tests indicated that neither WT (t15 = 1.26, 
P > .05) nor Nrg1 (t15 = 0.68, P > .05) animals showed 
an increased preference for the displaced vs stationary 
object.
Recency Discrimination [“What–Where”] Analysis 
Using Exploration Times. Repeated measures ANOVA 
showed no main effect of displacement on mean time 
spent exploring stationary objects vs displaced objects 
(F1,27 = 2.17, P > .05). There were no effects of genotype 
(F1,27 = 0.21, P > .05), sex (F1,27 = 1.03, P > .05), or geno-
type × sex interaction (F1,27 = 0.25, P > .05; figure 3D).
Comparative Metabolomic Analysis of Brain Tissue in 
TM-Domain Nrg1 Mutants
To determine the in vivo actions of  TM-domain muta-
tion of  Nrg1, we applied high-resolution mass spec-
trometry to Nrg1 mutants and WT littermate brain 
tissue. From the results of  PCA, it was observed that 
genotype had a significant influence on the metabo-
lite profiles observed because both groups (Nrg1 and 
WT) were clearly distinguishable (figure 4). Significant 
changes in multiple polar metabolites and associated 
pathways were observed (tables 1 and 2). Of  particular 
note was the evidence for aberrant lipid metabolism, 
particularly down-regulation of  phosphatidylcholine 
(PC) and phosphatidylethanolamine (PE) lipid classes, 
in the Nrg1 mutant. In addition, abnormalities in mul-
tiple brain metabolites across both purine metabolism 
and neuraminic pathways in Nrg1 mutants provide con-
vergent evidence for an influence of  NRG1 on these 
processes. Increased levels of  serine, 4-aminobutanoate, 
Fig. 2. Effects of acute antipsychotic administration on pre-pulse 
inhibition (PPI) disruption in Nrg1 mutants. (A) PPI in Nrg1 
mutants vs WT is selectively enhanced by acute administration 
of clozapine (1.0 mg/kg) at the 100 dB pulse intensity level 
across all of the prepulse intensity levels (4, 8, and 16 dB above 
background) (P < .01); †P < .01 vs vehicle-treated Nrg1 mice. 
However, antipsychotic treatment also increased PPI values 
in a genotype-independent manner (P < .01); **P < .01 vs 
vehicle-treated controls. Data are mean % PPI ± SEM. (B) PPI 
disruption in vehicle-treated Nrg1 mutants vs WT is reversed 
by acute administration of clozapine (1.0 mg/kg), but not 
haloperidol (0.5 mg/kg) or amisulpride (5.0 mg/kg) at the 120 
dB pulse intensity level and 4 dB prepulse intensity (P < .05); 
*P < .05 vs vehicle-treated WT mice; †P < .05 vs vehicle-treated 
Nrg1 mutants. Amisulpride (5.0 mg/kg) increased PPI at the 120 
dB pulse intensity and 16 dB prepulse intensity levels in Nrg1 
mutants (P < .05); †P < .05 vs vehicle-treated Nrg1 mutants). 
These data are mean % PPI ± SEM. Data were collected at Royal 
College of Surgeons in Ireland (RCSI), Dublin, Ireland (see 
online supplementary material).
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and acetylcholine are consistent with the known involve-
ment of  NRG1 in neurotransmitter function.13
Discussion
LI is a paradigm with high construct validity to model the 
disrupted attentional salience processes of schizophrenia, 
and has received robust validation as a pharmacological 
and genetic model of processes related to schizophre-
nia.20 The majority of studies have identified abnormal 
LI, as either inappropriately present or absent depending 
on symptom profile, in schizophrenia patients, patients’ 
relatives and individuals with high, psychometrically 
defined levels of schizotypy.25 Previous studies conducted 
in mutant mice containing heterozygous deletion of the 
Nrg1 Type 1 immunoglobulin-like (Ig) domain demon-
strated a selective LI deficit in terms of an ambulatory 
activity-based LI measure.46 However, it should be noted 
that the latter study did not utilize appropriate non–pre-
exposed condition controls, thereby rendering the result 
somewhat inconclusive. In addition, on a background of 
reports of up-regulation of NRG1 protein and increased 
NRG1 signaling in schizophrenia patients,4 neonatal, 
peripheral administration of NRG1 type 1 protein in 
mice has been shown to produce adult deficits in PPI and 
LI using a fear conditioning task, which were reversed 
by antipsychotic treatment.47 The present study demon-
strated intact LI in Nrg1 mutants, with male Nrg1 mutants 
Fig. 4. PCA separation of Nrg1 (n = 4) and WT (n = 4) mice 
based on 277 metabolites in positive ion mode.
Fig. 3. Episodic memory in Nrg1 HET vs WT mice using the “what–where–when” task. (A) Based on the discrimination ratio measure, 
male Nrg1 mutants display increased preference for “old” vs “new” objects relative to male WT, and this effect is contrary to the 
preference observed for female Nrg1 mutants and WT (P < .05); *P < .05 vs WT mice. Data are mean discrimination ratios ± SEM. 
Dashed line = chance level (50%). (B) Increased time (sec) spent exploring recently introduced objects (“new”) vs old/familiar (“old”) 
objects (P < .05) during the test for recency-based discrimination. Split by sex, male Nrg1 mutants demonstrated significantly more 
time exploring the “old” object relative to the “new” object (P < .05); *P < .05 vs WT mice. No effect of genotype on preference for 
exploring “old” vs “new” was observed for female mice. Data are mean total exploration time (sec) ± SEM. (C) Using discrimination 
ratios, no significant difference in the exploration of “stationary” vs “displaced” objects was observed in either Nrg1 mutants or WT. 
Data are mean discrimination ratios ± SEM. Dashed line = chance level (50%). (D) No significant difference in the time spent engaged in 
exploration of “stationary” or “displaced” objects was seen for either Nrg1 mutants or WT mice (P > .05). No effect of genotype or sex. 
Data are mean total exploration time (sec) ± SEM.
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Table 1. Identified Lipid Metabolites Following High-Resolution Mass Spectrometric-Based Metabolomic Analysis of Male Nrg1 
Mutant Vs WT Brain Tissue
Name MW Rt Ratio P Value Direction
PI38:4 887.5644 4.3 0.49 .00979 ↓
PI38:5 885.5483 4.3 0.33 .00222 ↓
PS 44:12 880.5121 4.7 0.39 .01298 ↓
PI 36:4 859.533 4.3 0.41 .00376 ↓
PE44:10 840.5519 4.9 0.41 .04708 ↓
PC40:4 838.6319 5.5 0.30 .00316 ↓
PI34:1 837.547 4.7 0.51 .00266 ↓
PS40:6 836.5434 4.7 0.51 .00296 ↓
PS 40:7 834.5277 4.7 0.35 .00204 ↓
PC40:7 832.5847 5.4 0.30 .02157 ↓
PC38:5 808.5843 5.5 0.31 .00468 ↓
PC38:5 808.5841 6.7 0.41 .00018 ↓
3-O-Sulfogalactosylceramide C18:0 808.5601 4.1 0.58 .02621 ↓
PC38:6 806.5694 6.7 0.44 .00320 ↓
PE40:4 796.5853 5.0 0.50 .03287 ↓
Acyl phosphatidylglycerol (n-C12:0) 793.5567 5.0 0.49 .00200 ↓
PE40:6 792.5532 4.9 0.47 .00591 ↓
PE40:7 790.5374 5.0 0.44 .00209 ↓
PC36:1 788.616 5.5 0.45 .00495 ↓
PC36:2 786.6006 5.5 0.41 .00739 ↓
PC36:4 782.569 6.7 0.39 .00150 ↓
PE40:2 ether lipid 780.5902 4.9 0.47 .00431 ↓
PG36:0 779.5781 4.9 0.46 .01456 ↓
PE40:5 ether lipid 778.573 4.9 0.45 .04059 ↓
PG36:1 777.562 4.9 0.48 .00113 ↓
PG36:2 775.5463 4.9 0.42 .00052 ↓
PE40:7 ether lipid 776.5585 4.9 0.45 .00286 ↓
PE40:7 ether lipid 774.5428 4.9 0.43 .00252 ↓
PE38:4 768.5534 5.0 0.47 .00034 ↓
PE38:5 766.5378 5.0 0.48 .00748 ↓
PE38:6 764.5221 5.0 0.48 .00125 ↓
PC34:0 762.6007 6.7 0.44 .00121 ↓
PC34:1 760.5846 5.5 0.45 .00276 ↓
PC34:2 758.5694 6.7 0.47 .00220 ↓
PE38:5 752.5586 5.0 0.44 .00910 ↓
PG34:0 751.5465 5.0 0.44 .00329 ↓
PE38:5 ether lipid 750.5431 5.0 0.45 .00756 ↓
PG34:1 749.5308 5.0 0.48 .00018 ↓
PE38:7 748.5272 5.0 0.46 .00015 ↓
PC 34:0 ether lipid 746.6054 5.5 0.39 .02468 ↓
PE36:2 744.5535 5.0 0.53 .02876 ↓
PE36:4 740.5223 5.0 0.47 .00056 ↓
PC32:0 734.5691 5.5 0.48 .00285 ↓
PC32:1 732.5543 5.5 0.37 .00094 ↓
SM36:2 731.6058 6.8 0.42 .00186 ↓
SM36:2 729.5898 6.8 0.43 .00599 ↓
PE36:3 ether lipid 726.5433 5.0 0.39 .02084 ↓
PE ether lipid 36:1 724.5273 5.0 0.49 .00039 ↓
PC32:2 720.5899 6.8 0.39 .00308 ↓
PE34:1 718.538 5.0 0.52 .00339 ↓
PC30:0 706.5379 5.5 0.47 .00348 ↓
SPPC 16:0 703.5743 6.8 0.44 .00646 ↓
PE34:1 ether lipid 702.543 5.0 0.56 .04100 ↓
SP 18:0 566.551 4.7 0.49 .00766 ↓
SP 18:1 564.535 4.7 0.64 .03157 ↓
LPC18:0 524.3713 5.6 0.67 .01522 ↓
Dehydrosphinganine 300.2898 9.7 0.34 .01826 ↓
Choline phosphate 184.0734 20.1 1.89 .01232 ↑
Choline 104.1071 17.6 1.72 .03941 ↑
Note: Assignment of metabolites, molecular weights (MW), retention times (Rt), ratio values, P values, and direction of difference for 
Nrg1 mutants vs WT. All metabolites with P < .05 were significant after application of false discovery rate (FDR) statistics to the 287 
metabolites observed in positive ion mode. Codes for lipids: PI, phosphoinositol; PS, phosphoserine; PE, phosphoethanolamine; PC, 
phosphocholine; PG, phosphoglycerol; SM, sphingomyelin; SP, sphingosine.
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exhibiting a nonspecific decrease in suppression ratios 
across both the pre-exposed and non–pre-exposed con-
ditions. Reconciling contradictory data concerning the 
association between NRG1 and LI performance involves 
acceptance of differing underlying neural mechanisms 
governing the effects of mutation of Nrg1 on attentional 
tasks of relevance to schizophrenia. NRG1/ErbB4 acti-
vation modulates the signaling of cortical GABA inter-
neurons,48 and is also involved in glutamatergic49 and 
dopaminergic transmission.45,50,51 It has been proposed 
that the frontal-cingulate cortical circuit is implicated in 
NRG1-mediated function of attentional salience.48
Reduced PPI has been reported in humans carrying the 
rs3924999 mutation of the NRG1 gene, and patients with 
schizophrenia who exhibit abnormal PPI over-express 
this mutation relative to controls.52 Isoform-specific Nrg1 
or ErbB4 receptor gene hypomorphic mice, as well as 
mice genetically over-expressing the Nrg1 type I isoform, 
show disruption of PPI across a variety of parametric 
conditions.46,53,54 In contrast, phenotypic studies involv-
ing the TM-domain Nrg1 mutant have suggested that 
PPI deficits may not be a robust effect in this line; rather, 
PPI deficits in TM-domain Nrg1 mutants are suggested 
to be protocol- and site-specific.18,30 In the present study, 
PPI was measured in TM-domain Nrg1 mutants housed 
in separate laboratories in Dublin and Nottingham, as 
well as using different testing protocols. PPI disruption 
in Nrg1 mutants was consistently observed across both 
sites and testing conditions, which is consistent with some 
of the existing literature.43,55,56 Karl and colleagues57 have 
previously demonstrated environmental modification of 
expression of psychosis-relevant phenotypes in this Nrg1 
mutant line, and have reported particular sensitivity of 
the PPI phenotype of the Nrg1 mutant to housing condi-
tions and test protocols when tested in several Australian 
laboratories.18 Their conclusions are in line with the pres-
ent study findings, and may also provide insight into dis-
crepant Nrg1 × PPI findings between Australia, Dublin, 
and Nottingham. Although PPI disruption was demon-
strated in Nrg1 mice in both the Dublin and Nottingham 
test facilities, the nature and magnitude of the PPI defi-
cit differed across both sites; other reported PPI findings 
conducted in Dublin-based Nrg1 mutants have shown 
similar phenotypic variability.55,56 In the original report of 
PPI deficits in the TM-domain Nrg1 mutant,43 employing 
a similar protocol, mutants displayed a 10%–15% reduc-
tion in PPI relative to controls. In other studies where 
protocol-specific modification of PPI has been observed, 
genotypic effects have been restricted to specific prepulse 
intensities, and a similarly modest deviation from the 
WT profile has been reported.18 Behavioral phenotypes 
including increased novelty-induced hyperactivity and 
Table 2. Identified Metabolites and Metabolic Pathways Following High-Resolution Mass Spectrometric-Based Metabolomic Analysis 
of Male Nrg1 Mutant Vs WT Brain Tissue
Category + Name MW Rt Ratio P Value Direction
Neurotransmitters
 Acetylcholine 146.1176 15.5 2.84 .00122 ↑
 Serine 106.0500 17.1 1.37 .02371 ↑
 4-Aminobutanoate 104.0707 17.8 1.22 .04131 ↑
Amino acids
 Alanine 90.05508 16.6 1.19 .02528 ↑
 Leucine 132.102 13.5 3.43 .01247 ↑
 Asparagine 133.0609 16.9 1.92 .01548 ↑
 Histidine 156.0768 37.4 0.13 .00116 ↓
Amino sugar metabolism
 Glycosamine acetate 222.0972 10.9 1.29 .04619 ↑
 N-acetylneuraminate 310.1133 12.4 1.23 .04832 ↑
 Muramic acid 252.1081 16.1 1.23 .00223 ↑
Purines and pyrimidines
 Guanine 152.0566 15.8 0.20 .03994 ↓
 Cytidine 244.0929 18.9 1.35 .03496 ↑
 Uridine 245.0768 8.3 1.29 .03911 ↑
 dIMP 333.06 15.5 2.67 .00882 ↑
Miscellaneous
 Orthophosphate 98.98429 15.1 1.62 .02165 ↑
 Nicotinamide 123.0554 9.9 1.25 .03196 ↑
 DL-glyceraldehyde 3-phosphate 171.0053 14.0 4.81 .04883 ↑
 Phosphocreatine 212.0432 13.7 0.14 .04271 ↓
 Glutathione 308.0911 14.0 1.36 .03052 ↑
Note: Assignment of metabolites, classification of metabolic pathways, molecular weights (MW), retention times (Rt), ratio values, 
P values, and direction of difference for Nrg1 mutants vs WT. All metabolites with P < .05 were significant after application of false 
discovery rate (FDR) statistics to the 287 metabolites observed in positive ion mode.
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social interaction deficits, have been reliably and robustly 
observed in the TM-domain Nrg1 mutant.34 In contrast, 
both the Dublin and Nottingham PPI results indicate a 
very mild PPI deficit in this Nrg1 mutant line; data from 
our laboratory and others have confirmed that this Nrg1-
related PPI deficit is markedly sensitive to acute and, in 
particular, prolonged exposure to stress, as well as test 
protocols and minor environmental modifications.37,55
Antipsychotic treatment is associated with differen-
tial NRG1/ErbB4 expression in both brain and serum 
in human and animal studies.58–60 In patients with first-
episode schizophrenia, serum NRG1 expression was 
increased following 2 weeks of treatment with risperidone 
or quetiapine.59 NRG1-ErbB4 function is also involved in 
several neurotransmitter pathways implicated in antipsy-
chotic activity.59 Treatment with clozapine (where clini-
cal efficacy is associated with antagonism at 5-HT2A, 
5-HT2C, and other receptors in addition to dopamine 
D2-like receptors) has been shown to reverse both PPI 
deficits in ErbB4 partial knockout mice60 and LI in 
Ig-like domain Nrg1 mutant mice.46 However, while clo-
zapine selectively reversed novelty-induced hyperactivity 
in TM-domain Nrg1 mutants, an initial report suggested 
that it may not be effective against PPI disruption in this 
line.43 In the current study, it was demonstrated that clo-
zapine partially restored disrupted PPI in Nrg1 mutants 
at the 120dB pulse intensity, without altering baseline 
startle reactivity or PPI in WT. At the lower pulse inten-
sity of 100 dB, clozapine treatment selectively enhanced 
PPI in Nrg1 mutants, but a generalized increase in PPI 
values under these conditions was observed across all 
treatment conditions relative to vehicle-treated controls.
Haloperidol (a dopamine D2-like receptor antagonist) 
displayed no effect on Nrg1-mediated PPI disruption, 
while amisulpride (a dopamine D2/D3 receptor antago-
nist) selectively increased PPI in Nrg1 mutants at the 120 
dB pulse intensity, at a prepulse intensity (16 dB) which 
was intact in vehicle-treated Nrg1 mutants vs WT con-
trols. In light of the pleiotropic role for NRG1 in neuronal 
function, the locus of interaction between NRG1/ErbB4 
and antipsychotic activity is unclear. However, decreased 
phosphorylation of the NR2B subunit in brains of 
TM-domain Nrg1 mutants is normalized by clozapine,63 
suggesting a glutamatergic basis for this interaction. The 
present PPI results confirm a role for the NRG1-ErbB4 
signaling pathway as a putative modulator of antipsy-
chotic drug effects in this paradigm, as well as a target for 
discovery of new antipsychotic drugs.64,65
fMRI analyses conducted in healthy subjects have 
demonstrated that variation in the single nucleotide 
polymorphism rs35753505 in the NRG1 gene is asso-
ciated with differences in activation of specific brain 
areas during completion of an episodic memory task.66 
Specifically, activation in the cingulate gyrus, left middle 
frontal gyrus, bilateral fusiform gyrus, and left middle 
occipital gyrus was modulated by NRG1 genotype during 
the encoding phase of the task. During the retrieval phase, 
left middle occipital gyrus activation was associated with 
NRG1 variation. However, this study failed to demon-
strate any effect of NRG1 genotype on task performance. 
Studies employing the TM-domain Nrg1 mutant have 
demonstrated intact spatial learning and working mem-
ory,34 but impaired novel object recognition memory.35 
We sought to investigate the possibility of phenotypic 
effects of Nrg1 mutation on the recency-mediated “what–
when” and “what–where” object recognition components 
of an episodic memory task (figure 5). The results indi-
cated that male Nrg1 mutants show impairment in their 
memory for the “what–when” component of the episodic 
memory task, which was marked by increased explora-
tion for an old vs new object.
No conclusions could be drawn with respect to the 
spatio-temporal (“what–where”) component of this task, 
as neither WT nor Nrg1 mutants showed a preference for 
exploring the stationary vs displaced objects. The absence 
of exploratory preference on the “what–where” compo-
nent may be interpreted as an absence of spatial learning 
in both WT and Nrg1 mutants.67 However, it has been 
proposed that the absence of any preference in object 
exploration does not necessarily reflect a learning deficit. 
Episodic memory tested in a single day may be influenced 
by delays (50 min in the present study) between sample 
Fig. 5. Schematic drawing of the episodic memory task encompassing the “what,” “where,” and “when” components. Object locations: 
NC, north-center; SW, south-west; SC, south-center; SE, south-east; NW, north-west; NE, north-east. Adapted from Dere et al.67
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and test phases; at short delays, it is suggested that mem-
ory for a familiar object is intact and at longer delays it 
becomes weak.68 The absence of preference in the spatial 
aspect of the task may be attributed to a decline in inter-
est for object exploration in this third phase (sample 1, 
sample 2, and test) of object exposure; rates of explora-
tion for “what–where” (stationary vs displaced) objects 
are greatly reduced compared to exploration rates for 
“what–when” (old vs new) objects. Alternatively, spatial 
discrimination memory may be subject to interaction 
with recency.69 A recent study confirmed that the episodic 
memory task employed in the present study is subject to 
paradigmatic influences and indicates that the spatio-
temporal interaction in the existing protocol may con-
found recency-mediated memories.67 It should be noted, 
however, that the temporal element cannot be removed 
from the spatial memory aspect of this task, and this is 
not a standalone measure of spatial memory, but, rather, 
of spatio-temporal memory. In summary, these findings 
demonstrate that reduced function in the TM domain of 
Nrg1 has sex-specific effects on episodic-like memory via 
impairment of recency-based novel object discrimination 
in male Nrg1 mutants.
Lipids and constituent fatty acids are crucial for diverse 
functional roles in the brain, including membrane com-
position and signal transduction, which are compromised 
in schizophrenia.70,71 Studies employing dedicated lipido-
mics platforms have reported significant changes in phos-
photidylcholine (PC) and phosphotidylethanolamine 
(PE) groups, both of which are implicated in membrane 
composition, in schizophrenia patients, in a manner unre-
lated to antipsychotic treatment.72,73 More recent studies 
have demonstrated structural lipid alterations in brain 
areas implicated in schizophrenia in patients as well as 
mice mutant for a schizophrenia risk gene (G72/G30).74 It 
has been suggested that these modifications in lipid meta-
bolic pathways may contribute to neural dysconnectivity 
in schizophrenia.73 Consistent with our findings in the 
Nrg1 mutant, significantly lower concentrations of PC 
have been detected in postmortem brain tissue of patients 
with schizophrenia.76,77 The present study reported a spe-
cific decrease in PC 38.6 in Nrg1 mutant brain; postmor-
tem brain analyses, as well as studies conducted in plasma 
and platelet plasmalogens of patients with schizophrenia, 
have revealed similarly decreased levels of PC 38:6 in 
schizophrenia.76,78 PC 38:6 and its associated interacting 
proteins has been shown to play a role in diverse immune-
related and neurotrophin signaling pathways79; the latter 
pathway, in particular, plays an important role in the reg-
ulation of neuron differentiation and proliferation during 
brain development, as well as participating in neuronal 
plasticity process associated with learning and memory.80 
As NRG1 is a neurotrophic factor, these analyses are sug-
gestive of mechanisms by which genetic factors associ-
ated with schizophrenia may modify signaling pathways 
linked with disturbance of cognition in schizophrenia.
TM-domain Nrg1 mutant mice demonstrate differen-
tial susceptibility to several of the neurobehavioral and 
cellular/molecular effects of acute and chronic tetrahy-
drocannabinol (THC) and other cannabinoids relative 
to wildtype controls.81–83 A  recent study demonstrated 
abnormal concentrations of two lipids in the brain of 
TM-domain Nrg1 mice, increased endogenous can-
nabinoid anandamide in the amygdala and decreased 
2-arachidonoylglycerol (2-AG) in the hypothalamus.84 
In animal tissue, anandamide is generated from its mem-
brane precursor the glycerophospholipid N-arachidonoyl 
phosphatidylethanolamine (NAPE). The present find-
ing of abnormal glycerophospholipids such as choline 
in TM-domain Nrg1 mutant mice, taken together with 
the evidence that the endocannabinoid system is dys-
regulated in schizophrenia,85 highlight the importance 
of further research to advance our understanding of the 
mechanisms underlying the interaction between NRG1, 
the endocannabinoid system, and schizophrenia.
Several metabolites belonging to the neuraminate 
pathway were significantly affected in Nrg1 mutants. The 
most marked accumulation is of N-acetylneuraminic 
acid, the most abundant form of sialic acid found in 
mammalian cells. Sialic acid in the form of polysialic acid 
has been reported to be involved in schizophrenia and 
schizophrenia-like symptoms.86–88 Previous examination 
of differentially expressed proteins in the hippocampi of 
transmembrane-domain Nrg1 vs WT controls identified 
significantly decreased expression of fibroblast growth 
factor 14 (FGF14) and other growth factors.83 Polysialic 
acid, a linear polymer of sialic acid, has been shown to 
specifically bind fibroblast growth factors,89 and recent 
work has demonstrated that polysialic acid also exerts 
protective effects of on proteolytic cleavage of FGF2.90 
Elevated fibroblast growth factor receptor mRNA has 
been reported in the prefrontal cortex of patients with 
schizophrenia relative to controls.91 In addition, mice 
with genetic knockout of FGF14 demonstrate cognitive 
deficits analogous to those observed in schizophrenia, 
together with altered expression of cellular and molecu-
lar components of GABA and glutamatergic function in 
schizophrenia-associated brain areas.92 Further studies of 
the relationship between sialic acid and growth factors 
including NRG1 and FGFs are clearly warranted.
Nrg1 mutants also demonstrated altered brain expres-
sion of metabolites associated with the purine metabolism 
pathway. Homeostatic imbalance of purine catabolism 
has previously been reported in first-episode, antipsy-
chotic-naive patients with schizophrenia.93 Allopurinol, 
which acts as an inhibitor for xanthine oxidase, an 
enzyme involved in purine metabolism, has been pro-
posed as an adjunctive therapy for schizophrenia.94 It has 
been suggested that purine metabolism is an important 
contributor to the pathophysiological process that links 
oxidative stress to membrane dysfunction, changes in key 
neurotransmitters, and the development of schizophrenia 
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and other neuropsychiatric disorders.93,95 A  signifi-
cant increase of glutathione was also observed in Nrg1 
mutants relative to WT. Glutathione alleviates the effects 
of oxidative stress, acting as an antioxidant protecting 
cells from damage induced by reactive oxygen species, 
and altered glutathione metabolism has been reported in 
patients with schizophrenia.96
These results demonstrate that TM-domain Nrg1 
mutant mice demonstrate specific cognitive and metabolic 
phenotypes related to schizophrenia, including a mild PPI 
impairment which is sensitive to antipsychotic treatment, 
as well as a sexually dimorphic deficit in the “what–when” 
element of an episodic memory task. Nrg1 mutants also 
displayed alterations in lipid metabolism and other meta-
bolic pathways implicated in pathophysiological processes 
associated with schizophrenia. Several disorders, includ-
ing metabolic syndrome, diabetes, and cardiovascular 
disease, are characterized by changes in lipid metabolism. 
Patients with schizophrenia are at increased risk for meta-
bolic abnormalities,96,97 and several antipsychotic drugs, 
particularly clozapine and olanzapine, can cause adverse 
effects that are related to lipid metabolism (eg, weight 
gain, insulin resistance).44,98 This study has identified novel 
physiological mechanisms by which disruption of NRG1 
function might contribute to the emergence of schizophre-
nia-relevant phenotypes in adulthood.
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